<DOC>
	<DOCNO>NCT00234364</DOCNO>
	<brief_summary>In blind echocardiographic study investigate frequency valvular abnormality group Parkinson patient treat either ergot derive dopamine agonist ( pergolide cabergoline ) non-ergot derive dopamine agonist ( pramipexole ropinirole ) . The ability detect patient valvular abnormality clinical approach examine .</brief_summary>
	<brief_title>Pergolide Treatment Valvular Heart Disease</brief_title>
	<detailed_description>Some case report single study , include 78 Parkinson patient , find correlation treatment ergotamine derivative dopamine agonist ( pergolide ) restrictive valvular heart disease . The mechanism think former use anorectikum , fenfluramine drug stimulate 5HT-2B receptor . In blinded manner make physiologic echocardiographic examination 160 Parkinson patient treat either ergotamine non-ergotamine derivative dopamine agonist ( 80 patient group ) see whether Parkinson patient treat ergotamine derivative heart valvular disease</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Heart Valve Diseases</mesh_term>
	<mesh_term>Pergolide</mesh_term>
	<criteria>Parkinson patient last year treat minimum 6 month either ergotamine derivative nonergotamine derivative dopamine agonist ( latter include control ) Informed contest Control patient exclude treated ergotamine derivates last 12 month prior ergotamine derivates 6 month Patients know valvular heart disease prior diagnosis Parkinson</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2007</verification_date>
	<keyword>Pergolide</keyword>
	<keyword>Ergotamine derivates</keyword>
	<keyword>Valvular heart disease</keyword>
</DOC>